藥華醫藥股份有限公司
藥華醫藥股份有限公司（PharmaEssentia Corporation）從事人類疾病治療藥物之研發。主要產品為長效型干擾素（Ropeginterferon alfa-2b），用於治療骨髓增生性腫瘤（如真性紅血球增多症）。亦開發癌症免疫與中性粒細胞減少症藥物。公司成立於 1990 年，總部位於台灣台北。
今日上漲 9.77%，股價站回短期均線。該股 RSI(6) 為 75.6，處於偏高區間，短線追高風險提升。股價站上5日、20日、60日、120日均線。短中期均線呈多頭排列，趨勢偏多。KD 指標偏高（K=81.1），追高宜謹慎；MACD 柱狀體為正值，維持多方動能。 （自動產生 · 非投資建議）
| 日期 | 外資 | 投信 | 自營商 | 合計 |
|---|---|---|---|---|
| 08-11 | +1,761 | -1 | +29 | +1,789 |
| 08-10 | +864 | +68 | -50 | +882 |
| 08-07 | -269 | +11 | +3 | -255 |
| 08-06 | +180 | -2 | -22 | +156 |
| 08-05 | -49 | +46 | +11 | +8 |
| 08-04 | -492 | +26 | -46 | -512 |
| 08-03 | +151 | 0 | +1 | +151 |
| 07-31 | -627 | +7 | +52 | -568 |
| 07-30 | +23 | +5 | -3 | +25 |
| 07-29 | +443 | +8 | +7 | +457 |
| 07-28 | -352 | 0 | -2 | -354 |
| 07-27 | -457 | +125 | +19 | -313 |
| 07-24 | -193 | +2 | +2 | -189 |
| 07-23 | +400 | -34 | +10 | +376 |
| 07-22 | -303 | +7 | -23 | -318 |
| 07-21 | -385 | +15 | -4 | -374 |
| 07-20 | -353 | +2 | +21 | -329 |
| 07-17 | +506 | -83 | -11 | +412 |
| 07-16 | -958 | +37 | -28 | -949 |
| 07-15 | -384 | -5 | +20 | -369 |
| 07-14 | +763 | +30 | +16 | +810 |
| 07-13 | -390 | +53 | +1 | -336 |
| 07-09 | -1,297 | -106 | -29 | -1,433 |
| 07-08 | -253 | +38 | -12 | -227 |
| 07-07 | -380 | +136 | +6 | -238 |
| 07-06 | -93 | +109 | -1 | +15 |
| 07-03 | +9 | +33 | -19 | +23 |
| 07-02 | -74 | +41 | +4 | -29 |
| 07-01 | +103 | +83 | +4 | +190 |
| 06-30 | +644 | +6 | -13 | +638 |
| 06-29 | +440 | -1 | +35 | +473 |
| 06-26 | +74 | +116 | -17 | +172 |
| 06-25 | +344 | +31 | -25 | +351 |
| 06-24 | +269 | +306 | -4 | +571 |
| 06-22 | +132 | +72 | -2 | +203 |
| 06-18 | +887 | +11 | +8 | +906 |
| 06-17 | +807 | +7 | +3 | +817 |
| 06-16 | +449 | -11 | +3 | +441 |
| 06-15 | +564 | -13 | +28 | +580 |
| 06-12 | +88 | -1 | +3 | +90 |
| 06-10 | +973 | -10 | -2 | +961 |
| 06-09 | +1,105 | +314 | -23 | +1,396 |
| 06-08 | -8 | 0 | +4 | -5 |
| 06-04 | +527 | +24 | +3 | +555 |
| 06-03 | -440 | +40 | -6 | -406 |
| 06-02 | -1,649 | +55 | -38 | -1,632 |
| 06-01 | +392 | +84 | -13 | +463 |
| 05-29 | +1,017 | +150 | +3 | +1,170 |
| 月份 | 營收 | MoM% | YoY% |
|---|---|---|---|
| 2026/06 | 23.33 億 | -5.1% | +94.9% |
| 2026/05 | 24.58 億 | +19.1% | +108.5% |
| 2026/04 | 20.64 億 | +6.4% | +68.3% |
| 2026/03 | 19.40 億 | +21.2% | +64.3% |
| 2026/02 | 16.00 億 | +1.2% | +56.6% |
| 2026/01 | 15.81 億 | -17.8% | +49.8% |
| 2025/12 | 19.24 億 | +23.8% | +64.0% |
| 2025/11 | 15.53 億 | +10.6% | +53.0% |
| 2025/10 | 14.04 億 | +6.5% | +53.6% |
| 2025/09 | 13.18 億 | +3.4% | +41.3% |
| 2025/08 | 12.74 億 | -2.1% | +41.4% |
| 2025/07 | 13.02 億 | - | +48.0% |